Smokers who make the decision to quit will experience immediate health benefits, including a rapid reduction in their risk of atrial fibrillation (A-Fib), according to new research published in JACC: Clinical Electrophysiology. The study, conducted by Dr. Gregory Marcus, a cardiologist at the University of California, San Francisco, offers compelling evidence for smokers to quit, showing that it’s never too late to avoid the damaging effects of smoking on heart health.

Dr. Marcus, the senior author of the study, emphasized that A-Fib can be prevented even in individuals who have smoked for years. "The findings provide a compelling new reason to show current smokers that it’s not too late to quit, and that having smoked in the past doesn’t mean you’re ‘destined’ to develop A-Fib," Marcus explained. "Even for the current and longtime smoker, A-Fib can still be avoided."

What is Atrial Fibrillation (A-Fib)?

"There’s strong evidence that smoking increases the risk of A-Fib," Marcus said. "But the benefits of quitting smoking have been less certain." With this in mind, his team sought to determine whether quitting could significantly lower a person’s risk of developing A-Fib, or if the risk would remain the same.

The research team analyzed data from over 146,700 current and former smokers, tracking their smoking habits and health over a 12-year period using data from the UK Biobank database. The results were promising: former smokers had a 13% lower risk of developing A-Fib compared to current smokers, while those who quit during the study saw an 18% reduction in their risk.

"This is likely a testament to the potency of reducing atrial fibrillation risk pretty shortly after quitting," Marcus said in a statement from the American College of Cardiology.

The findings highlight the importance of quitting smoking, not only for general health but specifically for reducing the risk of serious heart conditions like A-Fib.

Tips for Quitting Smoking

Quitting smoking is one of the most effective ways to lower the risk of A-Fib and improve overall heart health. While it can be challenging, the benefits of quitting are clear and immediate. Here are some tips to help you quit smoking successfully:

1. Choose a specific date to quit smoking and stick to it. Prepare yourself mentally and physically for this change.

2. Reach out to family, friends, or a support group to help keep you accountable. Sharing your goals with others can provide encouragement.

3. Options like nicotine patches, gum, or lozenges can help ease withdrawal symptoms and reduce cravings.

4. Identify situations that make you want to smoke, such as stress or social gatherings, and find healthy ways to cope with them.

5. Regular exercise can help distract you from cravings and improve your mood during the quitting process.

6. Drinking water can help flush nicotine out of your system faster, reducing cravings.

7. Activities like yoga, meditation, or deep breathing exercises can help manage stress, a common trigger for smoking.

Quitting smoking offers immediate and significant benefits, particularly in reducing the risk of atrial fibrillation. The latest research provides smokers with more motivation to quit, showing that it's never too late to take control of their heart health.

More than a quarter of Americans (28%) misrepresented symptoms to obtain antibiotics for themselves, while 27% did so to get antibiotics for a child in their care, according to an alarming survey.

The nationwide survey of nearly 1,000 people, published in JAMA Network Open, found that common reasons included feeling very sick, believing antibiotics were the only effective treatment and needing to recover quickly to return to work or school.

The findings highlight the need for better communication between doctors and patients so that concerns are heard and symptoms are appropriately treated, whether or not antibiotics are needed.

“Now that we have a clearer picture of how common these behaviors are and the reasons behind them, the next step is to look at strategies that help patients express their preferences and communicate what they’re feeling to their provider, and for their provider to hear them, understand their concerns, and reassure them,” said Alistair Thorpe, research assistant professor of population health sciences at the University of Utah Health and one of the study's first authors.

What Did The Survey Reveal?

Among respondents, 28% said they had deliberately exaggerated or fabricated symptoms to obtain antibiotics for themselves, while 27% had done so for a child in their care.

The most common reason was feeling that they or their child were very sick and believing antibiotics were the only treatment that could help.

“It is a tough situation,” Thorpe said. “People are experiencing unpleasant symptoms, and they can have this strong feeling that antibiotics are the only thing that can help them feel better. Being told to just rest and wait is a hard thing to do, and if you think there’s something that could make you feel better, it’s a very hard impulse to override.”

Other reasons included needing to recover quickly to return to work or school and wanting greater control over treatment decisions.

Why Is Taking Unnecessary Antibiotics Dangerous?

Antibiotics treat bacterial infections but do not work against viral infections, which commonly cause cold- and flu-like symptoms. They can also cause side effects.

“These medications are not totally benign for the patient,” explained Andrea Levy, Professor of social sciences at Connecticut State Community College Middlesex and one of the study's first authors. “And antibiotic use contributes to increasing antimicrobial resistance, which is a broader public health concern.”

Unnecessary antibiotic use contributes to antimicrobial resistance (AMR), making bacterial infections harder to treat.

Accurate symptom reporting is therefore important. Doctors need a clear picture of a patient's symptoms to determine whether antibiotics are necessary and avoid prescribing them when they are unlikely to help.

Why Are Children At High Risk With Antibiotic Misuse?

Children commonly receive antibiotics for infections such as ear infections and respiratory illnesses. However, many childhood infections are caused by viruses, against which antibiotics are ineffective.

Unnecessary antibiotic exposure can cause side effects, including diarrhoea, nausea and allergic reactions. It can also contribute to antimicrobial resistance, making future bacterial infections harder to treat.

Repeated antibiotic use may also disrupt the developing gut microbiome, which plays a role in digestion and immune function.

Why Do Patients Misrepresent Symptoms And How Can It Be Prevented?

The researchers emphasise that the findings are not intended to blame patients or caregivers.

“There are very understandable reasons that we can sympathize with about why patients might feel the need to misrepresent symptoms, or why caregivers might do so on behalf of their children,” Levy said. “We’re simply saying: perhaps there’s a better way.”

Past experiences with healthcare providers may influence these decisions. People were more likely to exaggerate symptoms if a doctor had previously dismissed or downplayed their concerns.

Another factor is the mistaken belief that antibiotics helped someone recover from an earlier viral infection. Since viral infections usually resolve on their own, patients may incorrectly attribute their recovery to antibiotics rather than the body's natural healing process, Thorpe explained.

The findings highlight the need for better communication between doctors and patients.

Healthcare providers need to reassure patients that their symptoms are being heard and taken seriously, even when antibiotics are not appropriate.

Public health officials in Stanislaus County, California, have reported four mpox cases. Two are confirmed as Clade I, while testing is underway for the other two.

Three individuals had no recent international travel history, raising concerns about local transmission. The travel history of the fourth person is still being assessed.

“Historically, Clade I mpox cases in the US were linked to international travel. However, since August 2026, more cases have been reported among people without recent international travel,” health officials said.

The cases suggest possible community transmission. However, county officials say the risk to the general public remains low.

“While we have identified four cases in our county, we want residents to know that the risk to the general public remains low,” Dr. Thea Papasozomenos, Stanislaus County Public Health officer, said.

US Reports Sustained Clade I Mpox Transmission

The Center for Outbreak Response Innovation (CORI), supported by Johns Hopkins Bloomberg School of Public Health and the CDC's Center for Forecasting and Outbreak Analytics, has classified the US as being in Scenario 4: Sustained Transmission for Clade I mpox.

This indicates ongoing person-to-person transmission chains in some jurisdictions, primarily among adults with multiple sexual partners, including sex workers and men who have sex with men (MSM).

The CDC reported more than 90 Clade I cases across at least 23 states and Puerto Rico as of October 14, 2026. Domestic transmission had been reported in 10 jurisdictions, with more cases involving people without recent international travel.

Why Is Clade I Mpox A Concern?

Clade I has historically been associated with more severe illness and higher fatality rates than Clade II. Its historical case-fatality rate has been estimated at 1% to 10%, compared with approximately 1% to 4% or lower for Clade II.

The 2024 global outbreak was driven largely by Clade I, particularly the Clade Ib sub-lineage. On August 14, 2024, the World Health Organization (WHO) declared the outbreak a Public Health Emergency of International Concern (PHEIC).

What Is Mpox?

Mpox is a viral zoonotic disease caused by the monkeypox virus, which belongs to the Orthopoxvirus genus, the same genus as the smallpox virus.

It spreads through close contact with infected people, including skin-to-skin and sexual contact, exposure to sores or bodily fluids, and contaminated items such as bedding and towels. Transmission can also occur through contact with infected animals.

What Are The Symptoms Of Mpox?

Symptoms generally appear 5 to 21 days after exposure and include:

• Skin rash
• Fever
• Sore throat
• Headache
• Muscle and body aches
• Fatigue
• Swollen lymph nodes

Most people recover within two to four weeks. However, severe illness can occur, particularly in children, pregnant women and immunocompromised people.

How Can Mpox Be Prevented?

Prevention measures include:

• Avoiding contact with potentially infected animals.
• Washing hands frequently.
• Avoiding close contact with infected people and contaminated belongings.
• Isolating infected individuals.
• Getting vaccinated if at increased risk of exposure.

New Mpox Vaccine Shows Promise

The JYNNEOS vaccine is recommended for people at increased risk of mpox exposure.

BNT166a, an mRNA-based mpox vaccine developed by BioNTech, has shown encouraging early results in its first human trial. The vaccine was generally safe and well tolerated, triggering strong antibody responses across all dose levels.

The Union Ministry of Health and Family Welfare has proposed three separate amendments to the Drugs Rules, 1945, to strengthen pharmaceutical quality control, manufacturing accountability and patient safety.

The proposals include immediate suspension of manufacturing licences for drugs failing specified critical quality tests, stricter microbial monitoring in sterile manufacturing areas, and mandatory authorisation of qualified personnel for batch release.

The announcements aim to strengthen India's drug regulatory framework and align manufacturing standards with international guidelines.

Immediate Suspension Of Licences For Drugs Failing Critical Quality Tests

Also read: India To Introduce QR Code Verification for Vaccines And Cancer Drugs: Here's What Patients Can Check

In a significant move to enable faster action against substandard medicines, the Ministry has proposed immediate suspension of manufacturing licences for drugs declared Not of Standard Quality (NSQ) on specified critical parameters.

Under the existing provisions, suspension or cancellation of a manufacturing licence involves a prescribed regulatory process, including the issuance of a show-cause notice. This can create a time gap between the identification of a quality failure and regulatory action, during which the drug may remain in circulation.

To address this, the proposed amendment would allow the Central Licensing Approving Authority or the State Licensing Authority, as applicable, to immediately suspend the manufacturing licence upon receiving a Government Analyst's report declaring a drug NSQ on any of the following parameters:

• Assay
• Dissolution
• Related substances
• Impurities
• Sterility

These parameters are critical to determining the quality and safety of medicines. The proposed provision seeks to enable prompt intervention and minimise potential risks to patients.

Stricter Microbial Monitoring In Sterile Drug Manufacturing

Read More: Centre Bans Cough & Cold Medicines For Children Under 4: What Parents Need To Know

The Ministry has proposed amendments to Schedule M of the Drugs Rules, 1945, to revise microbial contamination limits in Grade A clean areas in line with the World Health Organization's (WHO) Good Manufacturing Practices (GMP) guidelines for sterile pharmaceutical products.

Grade A areas are critical zones in sterile pharmaceutical manufacturing, where exposed products, containers and sterilised components are handled. Maintaining strict microbial controls in these areas is essential to preventing contamination and ensuring product safety.

The proposed revision addresses differences between the existing Schedule M requirements and WHO guidelines. It also provides for any microbial growth detected in Grade A areas to trigger an investigation, in accordance with WHO guidance.

The amendment aims to strengthen contamination monitoring and bring India's sterile manufacturing standards in line with internationally recognised benchmarks.

The development comes in the backdrop of an episode involving India’s biggest drug maker Sun Pharma, which was recently ordered to halt production at its manufacturing plant in Assam after reports of contamination in some of the eye drops made there.

Mandatory Authorization For Drug Batch Release

In another proposal, the Ministry has sought to make it mandatory for drug manufacturers to formally designate a suitably qualified and experienced person responsible for batch release.

Although manufacturers are currently required to provide details of competent technical staff responsible for manufacturing and testing while applying for licences, the rules do not specifically require them to identify the person authorised to release drug batches.

Under the proposed framework, manufacturers applying for licences under the relevant provisions of the Drugs Rules, 1945, would have to:

• Designate a qualified and experienced person responsible for batch release.
• Maintain prescribed records for every batch manufactured.
• Follow a prescribed format for the Batch Release Certificate.

Batch release is a critical stage in pharmaceutical manufacturing. It involves reviewing quality parameters and relevant documentation before a batch is cleared for distribution.

The proposed requirements seek to establish clear accountability for batch-release decisions, improve traceability and strengthen quality assurance.